A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of lnvestigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02B Ph 1/2 Substudy of 1L Oncological Treatment(s) in Advanced MEL

Brief description of study

The purpose of the study is to assess the efficacy of investigational treatment arms (pembrolizumab monotherapy or a unique pembrolizumab-based/ non-pembrolizumab-based combination) in participants with 1 L advanced melanoma to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/pembrolizumab monotherapy. We want to evaluate the antitumor effect of various investigational agents in combination with or without pembrolizumab or pembrolizumab monotherapy. This study has an adaptive design in which treatments are added/or inactivated on an ongoing basis.


Clinical Study Identifier: s20-01136
ClinicalTrials.gov Identifier: NCT04305054
Principal Investigator: Janice Mehnert.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.